PMID- 16491609
OWN - NLM
STAT- MEDLINE
DCOM- 20060328
LR  - 20191026
IS  - 1543-1894 (Print)
IS  - 1543-1894 (Linking)
VI  - 120
DP  - 2006
TI  - Detection of HER2 gene amplification by fluorescence in situ hybridization in 
      breast cancer.
PG  - 309-22
AB  - Fluorescence in situ hybridization (FISH) is increasingly recognized as the most 
      accurate and predictive test for both HER2 gene amplification or expression and 
      response to Herceptin therapy in breast cancer. Diagnostic procedures for FISH 
      require rigorous quality control, as with all diagnostic procedures, which rely 
      on standardized methodologies. We describe the use of FISH for HER2 in our own 
      laboratory, based on more than 4000 diagnostic assays, and the optimal approaches 
      to scoring HER2 gene amplification in breast cancer.
FAU - Bartlett, John M S
AU  - Bartlett JM
AD  - Division of Cancer Sciences and Molecular Pathology, University Department of 
      Surgery, Endocrine Cancer Group and HER2 Reference Laboratory, University of 
      Glasgow, Glasgow Royal Infirmary, UK.
FAU - Forsyth, Amanda
AU  - Forsyth A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Methods Mol Med
JT  - Methods in molecular medicine
JID - 101123138
SB  - IM
MH  - Breast Neoplasms/diagnosis/*genetics
MH  - Chromosomes, Human, Pair 17
MH  - Female
MH  - *Gene Amplification
MH  - *Genes, erbB-2
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
EDAT- 2006/02/24 09:00
MHDA- 2006/03/29 09:00
CRDT- 2006/02/24 09:00
PHST- 2006/02/24 09:00 [pubmed]
PHST- 2006/03/29 09:00 [medline]
PHST- 2006/02/24 09:00 [entrez]
AID - 10.1385/1-59259-969-9:309 [doi]
PST - ppublish
SO  - Methods Mol Med. 2006;120:309-22. doi: 10.1385/1-59259-969-9:309.